Back

Semaglutide consistently reduces cardiovascular risk in patients with type 2 diabetes regardless of baseline cardiovascular risk level: post hoc analyses of the SUSTAIN trial programme

26 August 2018 (14:00 - 18:00)
Organised by:
Congress Presentation Part of: Poster Session 3 - Cardiac patients with comorbidities Antidiabetic Pharmacotherapy ESC Premium Access ESC Congress 2018

About the speaker

Photo
Professor Stephen Bain

Swansea University, Swansea (United Kingdom of Great Britain & Northern Ireland)

5 More presentations in this session

Presentation thumbnail
Professor J. Seufert (Freiburg, DE)
Abstract Slides
Presentation thumbnail
Professor S. Verma (Toronto, CA)
Abstract Slides
Presentation thumbnail
Professor C. Lang (Dundee, GB)
Abstract
Presentation thumbnail
Ms M. Panahi (London, GB)
Abstract Slides
Presentation thumbnail
Professor S. Martsevich (Moscow, RU)
Abstract Slides

Access the full session

Session thumbnail
Poster Session 3 - Cardiac patients with comorbidities

The Event

Event poster

ESC Congress 2018

26 August 2018 14:00 CET
You may be interested in
thumbnail
Congress Session
Guidelines in Practice: 2023 ESC Guidelines for the Management of Cardiovascular Disease in Patients with Diabetes
thumbnail
Congress Presentation
Antithrombotic therapy in diabetes
thumbnail
Congress Session
2023 ESC Guidelines for the Management of Cardiovascular Disease in Patients with Diabetes

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources